Human TRANCE/RANK L/TNFSF11 (肿瘤坏死因子相关激活诱导因子) ELISA KIT

Human TRANCE/RANK L/TNFSF11 (肿瘤坏死因子相关激活诱导因子) ELISA KIT

货号:BSEH-297-96T

规格:96T

品牌:Biosharp

     ELISA KIT, also known as enzyme-linked immunosorbent assay kit, is an experimental method with high sensitivity, strong specificity and good reproducibility. It can be used for serum and plasma of human, mouse, rat, pig and other species, it has been widely used because of its stable reagents, easy storage and simple operation. 

The double-antibody sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen.

Features:

1. High sensitivity, strong specificity and good reproducibility
2. Can be used for serum and plasma of human, mouse, rat, pig and other species
3. Stable reagents, easy storage and simple operation 
4. Double-antibody sandwich ELISA methods
5. For Research Use Only. Not for use in diagnostic procedures

货号 BSEH-297-96T
规格 96T
品牌 Biosharp
说明书下载 点击下载

研究新进展—乳腺癌中作为免疫调节剂的RANK通路使“cold”肿瘤变“hot”

研究新进展—乳腺癌中作为免疫调节剂的RANK通路使“cold”肿瘤变“hot”

 

虽然免疫检查点抑制剂已经改变了一些癌症的治疗前景,如黑色素瘤和非小细胞肺癌,但还有其他肿瘤类型在免疫学上通常被描述为cold”,对免疫治疗反应不好。许多乳腺肿瘤是“cold”类型的,免疫浸润低,对免疫检查点阻断反应差。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody,研究人员证明了对RANK通路的抑制将“cold”乳腺肿瘤转化为“hot”肿瘤,变为“hot”的肿瘤可能受益于免疫疗法。

由比利时Université Libre de Bruxelles的Christos Sotiriou博士和西班牙ellvitge Biomedical Research Institute的Eva González-Suárez博士领导的研究人员通过临床前和临床补充研究,研究了RANK信号在乳腺癌中的作用。在临床前研究中,科学家小组使用小鼠模型表明,肿瘤细胞中RANK的缺失导致肿瘤浸润淋巴细胞的增加,表达RANK的肿瘤诱导免疫抑制微环境,使它们能够逃脱免疫监视。此外,Bio X Cell’s Anti-RANKL antibody用于证明抑制RANK配体(RANKL)可提高小鼠模型对检查点抑制剂的敏感性。这些结果表明,在乳腺癌患者中靶向RANK途径可能改善免疫治疗的反应。

在他们研究的临床部分,作者分析了用抗RANKL单克隆抗体Denosumab治疗的二期D-BEYON临床试验患者的样本。虽然这项研究没有达到其降低肿瘤增殖的主要目的,但作者发现了Denosumab治疗后肿瘤浸润淋巴细胞和CD8+ T细胞的增加,表明RANKL抑制有可能促进这些“cold”肿瘤的免疫反应。治疗前的高血清RANKL水平预示着免疫调节,为识别可能受益于Denosumab治疗和免疫检查点抑制的患者提供了潜在的生物标志物。

随着免疫肿瘤学的不断发展,开发免疫cold”肿瘤检查点阻断应答的策略是该领域的一大挑战。这项研究的结果表明,通过靶向调节免疫反应的途径,如RANK途径,可以将“cold”肿瘤转化为“hot”肿瘤。研究Denosumab和检查点抑制剂组合的临床试验正在其他肿瘤类型中进行测试,本研究中提供的数据为乳腺癌的类似试验提供了理论依据。

以上研究成果发布在Nature Communications文献 ” Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells” ,该研究小组使用了BioXCellAnti-mouse RANKL antibody (clone IK22/5, Bio X Cell catalog no. BE0191) Anti-mouse CTLA-4 (CD152) (clone 9D9, Bio X Cell catalog no. BP0164) Anti-mouse PD-L1 (B7-H1) (clone 10F.9G2, Bio X Cell catalog no. BP0101) Rat IgG2a isotype control (clone 2A3, Bio X Cell catalog no. BP0089) Mouse IgG2b isotype control (clone MPC-11, Bio X Cell catalog no. BP0086),  成功应用在研究乳腺癌模型中。这个新通路的发现将为进一步开发肿瘤免疫治疗方法提供新思路。

文章原文链接:https://www.nature.com/articles/s41467-020-20138-8#Abs1

详情请咨询 BioXcell 中国代理上海金畔生物科技

全国服务热线: 15221999938            邮箱: sales@jinpanbio.com

深圳: 021-50837765      北京: 021-50837765      上海: 021-50837765          

广州: 021-50837765        香港: 021-50837765

代理品牌网站: www.jinpanbio.com

自主品牌网站: www.jinpanbio.cnet